Quality is one of four performance categories under the Merit-based Incentive Payment System (MIPS). To fully participate in the Quality performance category, you or your group need to report on:
- Six quality measures, one of which is required to be an outcome measure, if available. If an outcome measure is not available, then you have to submit a high priority measure. You or your group would also have to meet the data completeness requirement (report 100% of eligible encounters and provide answers for at least 75%) for each measure submitted.
- Submit a complete specialty measure set if the specialty measure set contains less than 6 measures.
Eligible clinicians can report less than 6 measures, or without an Outcome/High Priority Measure and be eligible for the full Quality incentive through the Eligible Measures Applicability (EMA) Process.
Which collection types are eligible for EMA?
The EMA process is only applied to the following collection types :
- MIPS clinical quality measures (MIPS CQMs) (formerly referred to as “Registry measures”);
- Medicare Part B claims measures (only available for small practices)
CMS doesn't apply the EMA process to Qualified Clinical Data Registry (QCDR) measures or eCQMs collected in Certified Electronic Health Record Technology (CEHRT) because the clinical relationship pattern analysis (previously known as cluster analysis) either doesn’t apply or can’t be done within the current QCDR or CEHRT certification requirements.
If you submit any QCDR measures or eCQMs, alone or in combination with Medicare Part B claims measures or MIPS CQMs, you are expected to submit 6 quality measures.
The EMA process:
- Uses a clinical relations test to see if you could have submitted more measures, including outcome and high priority measures
- Adjusts the scoring to accurately reflect how the clinical relations test affected your or your group’s performance
To learn more about the EMA analysis and how it affects your quality performance calculation and score, see:
EMA’s practical effect when you submit less than 6 quality measures:
For example, a clinician reporting the Anesthesiology clinically related quality measures (404, 424, 430 and 463) through a registry could score up to 40 points. Those 40 points are usually compared with a quality score target of 60 based on the required 6 measures (i.e. 10 points x 6 measures = 60 points). Under EMA, the quality performance category score is then re-weighted from 40 points to 60 points so the MIPS score for the clinician is not negatively impacted.
If the clinician also have zero eligible instances for measure 463 in the EMA cluster, measure #463 will be submitted to 0/0 and the 3 remaining anesthesiology measures will be re-weighted to 60 MIPS points. The maximum points available for each measure with a perfect performance rate (based on CMS published benchmarks) are shown in parenthesis. Measures without max points currently do not have historical benchmarks. Scores, based on performance for non-benchmarked measures, will be calculated post submission.
These are the 2025 sets of MIPS registry measures that get the score adjusted by EMA:
Anesthesiology Care
- #404 Anesthesiology Smoking Abstinence
- #424 Perioperative Temperature Management
- #430 Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy
- #463 Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)
CABG Care
- #164 Coronary Artery Bypass Graft (CABG): Prolonged Intubation (no historical benchmark)
- #167 Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure (no historical benchmark)
- #168 Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration (no historical benchmark)
- #445 Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG) (no historical benchmark)
Cardiac Stress Imaging
Cataract Care
- #191 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery (7 pt cap)
- #303 Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (no historical benchmark)
- #304 Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery (no historical benchmark)
- #389 Cataract Surgery: Difference Between Planned and Final Refraction
Computed Tomography
- #360 Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies
- #364 Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines
- #405 Appropriate Follow-up Imaging for Incidental Abdominal Lesions
- #406 Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients
Diagnostic Imaging
Endoscopy and Polyp Surveillance
- #185 Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use (7 pt cap)
- #320 Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients (7 pt cap)
Interventional Radiology
- #145 Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy
- #413 Door to Puncture Time for Endovascular Stroke Treatment (no historical benchmark)
- #465 Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries (no historical benchmark)
Pathology 1
- #249: Barrett’s Esophagus
- #250: Radical Prostatectomy Pathology Reporting
- #395 Lung Cancer Reporting (Biopsy/Cytology Specimens)
- #396 Lung Cancer Reporting (Resection Specimens)
- #397 Melanoma Reporting
Pathology 2
- #249: Barrett’s Esophagus
- #395 Lung Cancer Reporting (Biopsy/Cytology Specimens)
- #397 Melanoma Reporting
- #491 Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma
Pathology 3
- #249: Barrett’s Esophagus
- #250: Radical Prostatectomy Pathology Reporting
- #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)
- #396: Lung Cancer Reporting (Resection Specimens)
- #491: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma
Pathology 4
- #249: Barrett’s Esophagus
- #397: Melanoma Reporting
- #440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician
Pathology – Skin Cancer
- #397 Melanoma Reporting (7 point cap)
- #440 Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician (7 t cap)
Surgical Care
- #355 Unplanned Reoperation within the 30 Day Postoperative Period
- #357 Surgical Site Infection (SSI)
- #358 Patient-Centered Surgical Risk Assessment and Communication (7 pt cap)
There are also Specialty Measure Sets with Fewer than 6 Measures that get quality re-weighted:
Anesthesiology
- #404 Anesthesiology Smoking Abstinence
- #424 Perioperative Temperature Management
- #430 Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy
- #463 Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)
- #477 Multimodal Pain Management
Diagnostic Radiology
- #145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy
- #360: Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies
- #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines
- #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions
- #406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients
Electrophysiology
- #392 Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation (No historical benchmark)
- #393 Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision (No historical benchmark)
Hospitalists
- #5 Heart Failure (HF): AngiotensinConverting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) (7 pt cap on MIPS CQM)
- #8 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) (7 pt cap on MIPS CQM)
- #47 Advance Care Plan (7 pt cap)
- #130 Documentation of Current Medications in the Medical Record (7 pt cap)
Optometry
- #117: Diabetes: Eye Exam (7 pt cap on MIPS CQM)
- #130: Documentation of Current Medications in the Medical Record (7 pt cap)
- #226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- #238: Use of High-Risk Medications in Older Adults
- #374: Closing the Referral Loop: Receipt of Specialist Report
Radiation Oncology
- #102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (No historical benchmark)
- #143 Oncology: Medical and Radiation – Pain Intensity Quantified
- #144 Oncology: Medical and Radiation – Plan of Care for Pain (7 pt cap)
- #226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- #508: Adult COVID-19 Vaccination Status
Please note: You should submit all quality measures that apply to your scope of practice and not limit your submission to those measures contained within the clinical topic. The EMA process was established to support clinicians and groups who may not have 6 quality measures available for, and applicable to their practice.